Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Stomach Neoplasms 128Esophageal Neoplasms 127Esophageal Squamous Cell Carcinoma 77Adenocarcinoma Of Esophagus 36Pancreatic Neoplasms 30Colorectal Neoplasms 25Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 22Neoplasms 21Neoplasm Metastasis 19Ovarian Neoplasms 16Melanoma 12Lung Neoplasms 11Carcinoma, Squamous Cell 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Adenocarcinoma 10Endometrial Neoplasms 9Carcinoma, Renal Cell 9Advanced Gastric Cancer 9Squamous Cell Carcinoma of Head and Neck 8Peritoneal Neoplasms 8Colonic Neoplasms 8Carcinoma, Ovarian Epithelial 8Anus Neoplasms 8Digestive System Neoplasms 7Prostatic Neoplasms 6Cholangiocarcinoma 6Biliary Tract Neoplasms 6Uterine Cervical Neoplasms 5Sarcoma 5

Interventions

asciminib 1Paclitaxel 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
P1b: Advanced Solid Tumors × Paclitaxel × Gastrointestinal × Clear all
NCT04492033 2025-01-27

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Handok Inc.

Phase 1/2 Terminated
41 enrolled
GastrointestinalOther solid neoplasm

P1b: Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡